For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Exelixis Inc (NASDAQ: EXEL) closed at $40.88 down -1.23% from its previous closing price of $41.39. In other words, the price has decreased by -$1.23 from its previous closing price. On the day, 2.57 million shares were traded. EXEL stock price reached its highest trading level at $41.7 during the session, while it also had its lowest trading level at $40.66.
Ratios:
For a deeper understanding of Exelixis Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.09 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.06. For the most recent quarter (mrq), Quick Ratio is recorded 3.68 and its Current Ratio is at 3.75. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.08.
Leerink Partners Upgraded its Market Perform to Outperform on October 21, 2025, while the target price for the stock was maintained at $48.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 20 ’25 when Haley Patrick J. bought 10,648 shares for $41.78 per share.
JOHNSON DAVID EDWARD bought 27,532 shares of EXEL for $1,187,235 on Nov 25 ’25. The Director now owns 1,553,262 shares after completing the transaction at $43.12 per share. On Nov 20 ’25, another insider, Haley Patrick J., who serves as the EVP, Commercial of the company, sold 34,187 shares for $41.88 each. As a result, the insider received 1,431,757 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXEL now has a Market Capitalization of 11004999680 and an Enterprise Value of 10148353024. As of this moment, Exelixis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.21, and their Forward P/E ratio for the next fiscal year is 12.68. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.79 while its Price-to-Book (P/B) ratio in mrq is 5.07. Its current Enterprise Value per Revenue stands at 4.435 whereas that against EBITDA is 11.939.
Stock Price History:
The Beta on a monthly basis for EXEL is 0.40, which has changed by 0.14749098 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, EXEL has reached a high of $49.62, while it has fallen to a 52-week low of $31.90. The 50-Day Moving Average of the stock is 0.48%, while the 200-Day Moving Average is calculated to be 2.29%.
Shares Statistics:
For the past three months, EXEL has traded an average of 2.76M shares per day and 2582030 over the past ten days. A total of 268.10M shares are outstanding, with a floating share count of 259.61M. Insiders hold about 3.15% of the company’s shares, while institutions hold 95.93% stake in the company. Shares short for EXEL as of 1764288000 were 21360218 with a Short Ratio of 7.73, compared to 1761868800 on 19791732. Therefore, it implies a Short% of Shares Outstanding of 21360218 and a Short% of Float of 11.0.
Earnings Estimates
Investors are keenly observing as 13.0 analysts analyze and rate. The current performance of Exelixis Inc (EXEL) in the stock market.The consensus estimate for the next quarter is $0.69, with high estimates of $0.82 and low estimates of $0.59.
Analysts are recommending an EPS of between $3.18 and $2.16 for the fiscal current year, implying an average EPS of $2.92. EPS for the following year is $3.28, with 13.0 analysts recommending between $3.91 and $2.55.
Revenue Estimates
A total of 17 analysts believe the company’s revenue will be $609.25M this quarter.It ranges from a high estimate of $631.03M to a low estimate of $530.4M. As of. The current estimate, Exelixis Inc’s year-ago sales were $566.75MFor the next quarter, 17 analysts are estimating revenue of $624.59M. There is a high estimate of $667.6M for the next quarter, whereas the lowest estimate is $593.67M.
A total of 19 analysts have provided revenue estimates for EXEL’s current fiscal year. The highest revenue estimate was $2.35B, while the lowest revenue estimate was $2.3B, resulting in an average revenue estimate of $2.33B. In the same quarter a year ago, actual revenue was $2.17BBased on 19 analysts’ estimates, the company’s revenue will be $2.61B in the next fiscal year. The high estimate is $2.96B and the low estimate is $2.44B.
